

For: NOVEL SERINE PROTEASE BSSP5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner: Sita S. Pappu

Application No.: 09/856,319

Filed: May 21, 2001

Confirmation No.: 6685

Art Unit: 1636

Washington, D.C.

Atty.'s Docket: UEMURA=5

OR

OR

Date: August 15, 2002

AUG 1 9 2002

THE COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

TECH CENTER 1600/2900

Sir:

Transmitted herewith is a [] Amendment [XX] Response to Notification to Comply with Sequence Requirements + Sequence List + disk in the above-identified application.

[] Small Entity Status: Applicant(s) claim small entity status. See 37 C.F.R. §1.27.

No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA EQUALS
TOTAL	*	MINUS	** 20	0
INDEP.	*	MINUS	*** 3	0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

ADDITIONAL FEE
\$
B
5
5
6

OTHER THAN SMALL ENTITY RATE **ADDITIONAL** FEE 18 \$ 80 \$ 270 \$ TOTAL \$

If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 20, write "20" in this space.

If the "Highest Number Previously Paid for" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (total or independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment of the number of claims originally filed.

[XX] Conditional Petition for Extension of Time

If any extension of time for a response is required, applicant requests that this be considered a petition therefor.

It is hereby petitioned for an extension of time in accordance with 37 CFR 1.136(a). The appropriate fee required by 37 CFR 1.17 is calculated as shown below:

	Small Entity	Other Than Small Entity		
	Response Filed Within	Response Filed Within		
	[] First - \$ 55.00	[] First - \$ 110.00		
	[] Second - \$ 195.00	[] Second - \$ 390.00		
	[] Third - \$ 445.00	[] Third - \$ 890.00		
	[] Fourth - \$ 695.00	[] Fourth - \$ 1390.00		
	Month After Time Period Set Month After Time Period			
	[] Less fees (\$) already paid for month(s) extension Please charge my Deposit Account No. 02-4035 in the amount of \$			
()	Please charge my Deposit Account No. 02-4035 in the amount of \$	·		
[]	Credit Card Payment Form, PTO-2038, is attached, authorizing pay	ment in the amount of \$		
[]	A check in the amount of \$ is attached (check no.).		
[XX]	The Commissioner is hereby authorized and requested to charge an overnayment to Deposit Account No. 02-4035. This authorization a	•		

ection with this application or credit any ssociated with this communication, including any Extension of Time fee, not covered by check or specific authorization, but is also intended to include all fees for the presentation of extra claims under 37 CFR §1.16 and all patent processing fees under 37 CFR §1.17 throughout the prosecution of the case. This blanket authorization does not include patent issue fees under 37 CFR §1.18.

BROWDY AND NEIMARK

Attorneys for Applicant(s)

Allen C. Yun

Registration No. 37,971

Facsimile: Telephone:

(202) 737-3528 (202) 628-5197

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING WITH APPLICATION WITH PATENT APPLICATION WITH P

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comp with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
X	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7. Other:
App	olicant Must Provide:
X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry in the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	Rules Interpretation, call (703) 308-4216 CRF Submission Help, call (703) 308-4212 tentIn Software Program Support Technical Assistance
<u>:</u>	TO F GIOLOGE F ALEIRIN GOLWAIE

RECEIVED

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

AUG 1 9 2002